{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:28:33Z","timestamp":1790209713226,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Background<\/jats:title>\n Testosterone therapy is increasingly prescribed in cisgender women for sexual and metabolic indications and constitutes the cornerstone of gender-affirming hormone therapy in transgender men. However, the nature and certainty of cardiovascular safety evidence supporting testosterone use differ across clinical contexts.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To synthesize the available evidence on cardiovascular mortality associated with testosterone therapy in cisgender women and transgender men, with specific attention to study design, duration of follow up, and certainty of evidence. This review does not aim to directly compare cardiovascular risk between populations.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This systematic review was conducted in accordance with the PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420251009443). Randomized controlled trials evaluating transdermal testosterone therapy in cisgender women and observational cohort studies assessing testosterone therapy in transgender men were included. Risk of bias was assessed using the Cochrane RoB 2.0 tool and the Newcastle Ottawa Scale, and certainty of evidence was evaluated using the GRADE framework. Due to substantial clinical and methodological heterogeneity, quantitative meta-analysis was not performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirteen randomized controlled trials involving 2, 628 cisgender women receiving transdermal testosterone for periods ranging from 8 to 52 weeks reported no cardiovascular deaths. Thirteen observational cohort studies including 7, 837 transgender men receiving long term testosterone therapy reported 34 cardiovascular deaths, corresponding to an incidence rate of 1.81 per 1, 000 person years. The certainty of evidence was rated as moderate for short term outcomes in cisgender women and low to very low for long term cardiovascular outcomes in transgender men.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The available evidence on cardiovascular mortality associated with testosterone therapy differs substantially between cisgender women and transgender men, primarily reflecting differences in study design, follow up duration, and certainty of evidence rather than definitive conclusions regarding comparative cardiovascular risk. The absence of cardiovascular deaths in short-term randomized trials does not allow inference regarding long term cardiovascular safety, highlighting the need for adequately powered studies with extended follow-up and standardized outcome definitions.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n , identifier CRD420251009443.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1789504","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:26:38Z","timestamp":1770787598000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular mortality associated with testosterone therapy in cisgender women and transgender men: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Diogo Pinto da Costa","family":"Viana","sequence":"first","affiliation":[{"name":"Department of Gynecology, Brazilian Society for Research and Teaching in Medicine","place":["Florian\u00f3polis, Brazil"]},{"name":"Department of Gynecology, Brazilian Society of Obesity Medicine","place":["Florian\u00f3polis, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Caseri","family":"C\u00e2mara","sequence":"additional","affiliation":[{"name":"Department of Specialization in Clinical Anabolism, College of Governance, Engineering, and Education of S\u00e3o Paulo - FGE-SP","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio de Sousa Monte","family":"Alto","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Brazilian Society of Obesity Medicine","place":["Florian\u00f3polis, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-01603","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"104","author":"Davis","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-022-00613-0","article-title":"The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review","volume":"34","author":"Uloko","year":"2022","journal-title":"Int J Impot Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2262","article-title":"The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: A systematic review and meta-analysis","volume":"99","author":"Elraiyah","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2020.10.009","article-title":"International society for the study of women\u2019s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women","volume":"18","author":"Parish","year":"2021","journal-title":"J Sex Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society* Clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-23-0021","article-title":"Cardiovascular risk in transgender people with gender-affirming hormone treatment","volume":"5","author":"Masumori","year":"2023","journal-title":"Circ Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B8","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009073431002","article-title":"Transdermal testosterone treatment in women with impaired sexual function after oophorectomy","volume":"343","author":"Shifren","year":"2000","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000060256.03945.20","article-title":"Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women","volume":"10","author":"Goldstat","year":"2003","journal-title":"Menopause"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1582","article-title":"Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial","volume":"165","author":"Braunstein","year":"2005","journal-title":"Arch Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000158103.27672.0d","article-title":"Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial","volume":"105","author":"Buster","year":"2005","journal-title":"Obstet Gynecol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1747","article-title":"Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder","volume":"90","author":"Simon","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000179049.08371.c7","article-title":"Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial","volume":"13","author":"Davis","year":"2006","journal-title":"Menopause"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2005.01.002","article-title":"Treatment with percutanous testosterone gel in postmenopausal women with decreased libido \u2013 effects on sexuality and psychological general well-being","volume":"53","author":"Nathorst-B\u00f6\u00f6s","year":"2006","journal-title":"Maturitas"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000243567.32828.99","article-title":"Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study","volume":"13","author":"Shifren","year":"2006","journal-title":"Menopause"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/13697130701364644","article-title":"A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder","volume":"10","author":"El-Hage","year":"2007","journal-title":"Climacteric"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-8-200804150-00001","article-title":"Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: A randomized trial","volume":"148","author":"Davis","year":"2008","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707302","article-title":"Testosterone for low libido in postmenopausal women not taking estrogen","volume":"359","author":"Davis","year":"2008","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/13697131003675922","article-title":"Testosterone treatment of HSDD in naturally menopausal women: the ADORE study","volume":"13","author":"Panay","year":"2010","journal-title":"Climacteric"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12426","article-title":"Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial","volume":"11","author":"Fooladi","year":"2014","journal-title":"J Sex Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1210\/jc.2007-1809","article-title":"Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience","volume":"93","author":"Gooren","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00909.x","article-title":"Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals","volume":"5","author":"Meriggiola","year":"2008","journal-title":"J Sex Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1038","article-title":"A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12698","article-title":"Effects of three different testosterone formulations in female-to-male transsexual persons","volume":"11","author":"Pelusi","year":"2014","journal-title":"J Sex Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the european network for the investigation of gender incongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2019.06.014","article-title":"Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria","volume":"16","author":"Stoffers","year":"2019","journal-title":"J Sex Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000475","article-title":"Metabolic effects of cross-sex hormone therapy in transgender individuals in Taiwan","volume":"84","author":"Liu","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01067-z","article-title":"Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy","volume":"46","author":"Martinez-Martin","year":"2023","journal-title":"Hypertens Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20039","article-title":"Longitudinal changes in regional fat and muscle composition and cardiometabolic biomarkers over 5 years of hormone therapy in transgender individuals","volume":"297","author":"Lundberg","year":"2025","journal-title":"J Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008061","article-title":"Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy","volume":"7","author":"Roy","year":"2023","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13196001","article-title":"Assessing the influence of long-term gender-affirming hormone therapy on cardiovascular risk in transgender men through carotid intima\u2013media thickness","volume":"13","author":"Hamid","year":"2024","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1714","article-title":"Long-term effects of gender affirming hormone therapy (GAHT) on lipid profile","volume":"8","author":"Le","year":"2024","journal-title":"J Endocr Soc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00185-6","article-title":"Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria","volume":"9","author":"De Blok","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","article-title":"Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults","volume":"74","author":"Connelly","year":"2019","journal-title":"Hypertension"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1789504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:26:38Z","timestamp":1770787598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1789504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1789504"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1789504","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1789504"}}